Literature DB >> 7523544

The tumor markers TPA, TPS, TPACYK and CYFRA 21-1 react differently with the keratins 8, 18 and 19.

H Bodenmüller1, F Donié, M Kaufmann, D Banauch.   

Abstract

The commercially available tumor marker tests TPA, TPS, TPACYK and CYFRA 21-1 react with simple epithelium keratins. From clinical studies it can be deduced that the pattern of keratin recognition must be different for each of these tests. We therefore studied the reactivity of the keratin fragment combinations K8/K18 and K8/K19 in the different tests and determined the reactivity of the corresponding soluble antibodies with purified keratin 8, 18 and 19 in immunoblots. TPS and CYFRA 21-1 were found to distinguish clearly between the keratin fragment combinations K8/K18 (TPS) and K8/K19 (CYFRA 21-1). TPA and TPACYK reacted with both combinations, however, with different intensities. On immunoblots the CYFRA 21-1 antibodies reacted exclusively with K19, whereas the antibodies of the other assays reacted with at least 2 of the keratins investigated.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7523544     DOI: 10.1177/172460089400900202

Source DB:  PubMed          Journal:  Int J Biol Markers        ISSN: 0393-6155            Impact factor:   3.248


  7 in total

1.  Current Biomarkers for Precision Medicine in Breast Cancer.

Authors:  Soo Kyung Ahn; So-Youn Jung
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

2.  A novel immunoassay for the quantization of CYFRA 21-1 in human serum.

Authors:  An He; Tian-Cai Liu; Zhi-Ning Dong; Zhi-Qi Ren; Jing-Yuan Hou; Ming Li; Ying-Song Wu
Journal:  J Clin Lab Anal       Date:  2013-07       Impact factor: 2.352

Review 3.  Circulating tumour markers in breast cancer.

Authors:  Ettore Seregni; Antonio Coli; Nicola Mazzucca
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-05-04       Impact factor: 9.236

4.  NSE can predict the sensitivity to definitive chemoradiotherapy of small cell carcinoma of esophagus.

Authors:  Hongjiang Yan; Renben Wang; Shumei Jiang; Kunli Zhu; Rui Feng; Xiaoqing Xu; Xiangjiao Meng
Journal:  Med Oncol       Date:  2013-12-05       Impact factor: 3.064

5.  Clinical significance of serum CYFRA 21-1 in gastric cancer.

Authors:  B Nakata; Y S Chung; Y Kato; M Ogawa; Y Ogawa; A Inui; K Maeda; T Sawada; M Sowa
Journal:  Br J Cancer       Date:  1996-06       Impact factor: 7.640

6.  Cytokeratin 18 in plasma of patients with gastrointestinal adenocarcinoma as a biomarker of tumour response.

Authors:  L C Scott; T R J Evans; J Cassidy; S Harden; J Paul; R Ullah; V O'Brien; R Brown
Journal:  Br J Cancer       Date:  2009-07-14       Impact factor: 7.640

7.  CYFRA 21-1 serum levels in women with adnexal masses and inflammatory diseases.

Authors:  C Tempfer; L Hefler; H Heinzl; A Loesch; G Gitsch; H Rumpold; C Kainz
Journal:  Br J Cancer       Date:  1998-10       Impact factor: 7.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.